{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"The length of time post-transplant that the patient survives without any signs or symptoms of that cancer.","groups":[{"description":"All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).","id":"OG000","title":"All Trial Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Year 5","title":"5-year Disease-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}